Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) released its earnings results on Tuesday. The company reported ($0.83) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.83), Zacks reports. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.54 million. Xenetic Biosciences had a negative return on equity of 43.40% and a negative net margin of 182.99%.
Xenetic Biosciences Price Performance
Shares of XBIO traded down $0.14 on Thursday, reaching $3.15. 59,989 shares of the stock traded hands, compared to its average volume of 7,299. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.97. The stock’s 50-day moving average price is $3.98 and its 200-day moving average price is $3.98. The firm has a market cap of $4.85 million, a price-to-earnings ratio of -1.08 and a beta of 2.29.
About Xenetic Biosciences
See Also
- Five stocks we like better than Xenetic Biosciences
- What is the Dogs of the Dow Strategy? Overview and Examples
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Jeff Brown’s Exegesis AI Stock Picks
- What is the NASDAQ Stock Exchange?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.